Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The company has been sold to Shinshin Pharmaceuticals
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The drug is also intended for the treatment of glioblastoma multiforme
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
